Albumedix - Dedicated to Better Health
Albumedix is a science-driven, life-science company focused on enabling the creation of advanced therapies and biopharmaceuticals utilizing our high quality recombinant human albumin products and technologies. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago.
Our vision is to empower excellence in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally. As an example, we are proud to be working with domestic, national and international life science companies in these challenging times towards the urgent response against covid-19 - be it diagnostically, therapeutically and prophylactically.
Alderley Park is a place where world leading science, innovation and stylish living come together to create a place like no other.
Part of Bruntwood SciTech, a 50:50 joint venture between leading property company Bruntwood and Legal and General, Alderley Park is currently undergoing £247m investment. Home to the internationally-recognised Mereside bioscience campus, the Park offers more than 1m sq ft of high specification lab space, a range of scientific services and an accelerator delivering a comprehensive programme of business support for start-ups and scale-ups. It is also home to a vibrant and fast growing community of over 60 established and 150 pre-start up companies.
The newly re-developed 150,000 sq ft ‘Glasshouse’, opened in February 2020, offers high specification, collaborative workspace to tech companies and forward thinking, innovative businesses.
The Park is also home to a wide range of amenities including a conference centre complete with a 232 seat auditorium and meeting rooms, restaurant, gym and outdoor sports pitches. It also offers unrivalled 100GB connectivity, Enterprise Zone status, and is part of the Cheshire Science Corridor.
This is a place where people can live connected lives, in a community that will shape its own future. A place to do science, do business, work We can help you shape the future. and live differently, with no boundaries. Where people, work, life, ideas and conversations flow seamlessly together.
Nowhere else offers you so much room to breathe and space to think. Or such a canvas for being creative, individual and inventive.
If you believe that things don’t always have to be done the way people have always done them, if you want to keep evolving the way you do business, work and live, you’ll find Alderley Park a breath of fresh air.
Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.
The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.
We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.
Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.
Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.
As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.
At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.
Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.
Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.